Andreas du Bois, MD, PhD, on Ovarian Cancer: Niraparib, Trabectedin Plus Doxorubicin, Platinum, and Carboplatin
ESMO Virtual Congress 2020
Andreas du Bois, MD, PhD, of Kliniken Essen Mitte, discusses the NORA and INOVATYON studies of patients with recurrent ovarian cancer, detailing the findings for women in China with platinum-sensitive disease and women internationally who received trabectedin and pegylated liposomal doxorubicin (PLD) followed by platinum at disease progression vs carboplatin and PLD after disease progression (Abstract LBA29 and LBA30).
The ASCO Post Staff
Sumanta K. Pal, MD, of the City of Hope National Medical Center, discusses results from the COSMIC-021 study, which tested two different doses of cabozantinib, each with a standard dose of atezolizumab, administered to patients with metastatic advanced clear cell renal cell carcinoma. Dr. Pal reports on response rates and progression-free survival, as well as biologic correlates that may have influenced response (Abstract 702O).
The ASCO Post Staff
Erica L. Mayer, MD, MPH, of Dana-Farber Cancer Institute, discusses an initial analysis of phase III findings from the PALLAS trial, which suggested the benefits observed in the metastatic setting with palbociclib plus endocrine therapy did not translate into the earlier adjuvant setting for patients with hormone receptor–positive, HER2-negative breast cancer. Long-term follow-up is ongoing (Abstract LBA12).
The ASCO Post Staff
Cécile Le Pechoux, MD, of the Institut Gustave Roussy, discusses new findings from an international trial on an old controversy: What is the role of postoperative radiotherapy in locally advanced (stage III) non–small cell lung cancer? The researchers enrolled patients with completely resected disease and mediastinal N2 involvement (Abstract LBA3).
The ASCO Post Staff
David S. Hong, MD, of The University of Texas MD Anderson Cancer Center, discusses study findings on sotorasib, a novel, first-in-class, oral KRASG12C inhibitor. The agent demonstrated durable disease control in heavily pretreated patients with non–small cell lung cancer (Abstract 1257O).
The ASCO Post Staff
Lisa A. Carey, MD, of the University of North Carolina, discusses phase III results from two IMpassion trials, 130 and 131, which explored, respectively, atezolizumab plus nab-paclitaxel vs placebo plus nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer and first-line paclitaxel with or without atezolizumab for unresectable disease (Abstracts LBA15 and LBA16).
